We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ranbaxy Expands US Production Capacity Because of Import Alert
Ranbaxy Expands US Production Capacity Because of Import Alert
February 2, 2009
The FDA’s import alert for 30 generic drug products made at two Ranbaxy production facilities in India has caused the company to expand its U.S. manufacturing operations and take an estimated $50.8 million charge against earnings in 2008.